Efficacy and Safety of Benralizumab in Moderate to Very Severe COPD
with history of Frequent Exacerbations (RESOLUTE study)

What is the RESOLUTE Study?

The study is designed to determine if Benralizumab when added to standard therapy will decrease the risk of flare-ups in COPD It is an injected antibody against IL-5 receptors, and targets and removes eosinophils from the blood. Eosinophils are cells which are part of our immune system, but increased numbers can cause one type of airway inflammation, resulting in flare-ups in certain patients with COPD. It is already approved to be used in certain patients with asthma, and now is being tested for COPD.

Res
You might qualify for this if you have:
  • Moderate to severe COPD as determined by lung function tests
  • Have frequent flare-ups despite being on standard inhaler treatment. COPD flare-up is when you have an increase or new onset of cough, sputum, wheezing, shortness of breath or chest tightness which requires treatment with antibiotics, steroids, and/or hospitalizations.
  • High eosinophil level in blood
  • Have smoked at least 10 pack years, and are currently smoking or quit smoking
  • Have significant symptoms of COPD assessed by COPD Assessment Test (CAT) - A standard pulmonary questionnaire

What Will My Role Be in the Study?

If you participate, you will be randomly assigned to get  injections of either the study drug or placebo, every 4-8 weeks for one year. You will have a total of 11 clinic visits and 5 telephone visits. You will do questionnaires, lung function tests, blood tests and maintain a daily electronic diary for symptoms. You will receive compensation for clinic visits, and parking will be provided. You may also quality to receive your COPD inhaler at no cost

Doctor injecting vaccine to senior woman
Interested in a Research Study, Click Here For Our Registry Survey!
© 2024 Emphysema COPD Research Center

Thank You

For Contacting Us!

We’ll Respond to Your Message as Soon as Possible!